Stable Istotope Labelled Daclizumab Biosimilar – Anti-IL2RA mAb – Research Grade

Reference: PX-TA1038-SIL-1MG
Product nameStable Istotope Labelled Daclizumab Biosimilar - Anti-IL2RA mAb - Research Grade
SourceCAS 152923-56-3
Expression systemMammalian cells
Molecular weight143kDa
BufferPBS buffer PH7.5
Delivery conditionBlue Ice
Delivery Time3-5 days if in stock; 5-8 weeks if production needed
Storage conditionstore at -80°C
Aliases /SynonymsBIIB019,DAC HYP
Related ProductsPX-P4562
NoteFor research use only. Not suitable for clinical or therapeutic use.
ClonalityMonoclonal Antibody
LabellingArginine: 13C6,15N4 ; Lysine: 13C6,15N2, >99%
Isotopic Enrichment99%
Stability1 year

General information on Anti-IL2RA(Homo sapiens) (Daclizumab) Monoclonal Antibody

Daclizumab is a humanized IgG1 monoclonal antibody that binds to human interleukin 2 receptor (anti-Tac or anti-CD25)and composed of human >90%) and murine (10%) antibody sequences. The human sequence is derived from the constant domain of human IgG1 and the variable framework region of Eu myeloma antibody. The murine part was taken from the complementarity-determining regions of a murine anti-Tac antibody. Daclizumab has been used for preventing acute organ rejection in de novo allogeneic kidney transplantation when used simultaneously with immunosuppressive regimens such as cyclosporine and corticosteroid and in the treatment of adult patients with relapsing multiple sclerosis. These trademarks were Zenapax and Zimbryta, respectively.


There are no reviews yet.


Be the first to review “Stable Istotope Labelled Daclizumab Biosimilar – Anti-IL2RA mAb – Research Grade”

Your email address will not be published. Required fields are marked *

Contact us

Send us a message from the form below